{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:21:17Z","timestamp":1790526077754,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005031","name":"BARC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005031","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Applied Radiation and Isotopes"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.apradiso.2016.05.025","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T04:25:00Z","timestamp":1464150300000},"page":"196-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Evaluation of 177Lu-CHX-A\u2032\u2032-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers"],"prefix":"10.1016","volume":"114","author":[{"given":"Mythili","family":"Kameswaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Gamre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.V.","family":"Vimalnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haladhar Dev","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apradiso.2016.05.025_bib1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.apradiso.2011.01.026","article-title":"[177Lu]DOTA-anti-CD20: labeling and pre-clinical studies","volume":"69","author":"Audicio","year":"2011","journal-title":"Appl. Radiat. Isot."},{"issue":"Suppl. 6","key":"10.1016\/j.apradiso.2016.05.025_bib2","first-page":"S1","article-title":"Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer","author":"Bell","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.apradiso.2016.05.025_bib3","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2967\/jnumed.111.091629","article-title":"Targeted systemic radiotherapy with scVEGF\/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis","volume":"52","author":"Blankenberg","year":"2011","journal-title":"J. Nucl. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.apradiso.2016.05.025_bib4","first-page":"S1199","article-title":"177Lu-Bevacizumab a potential melanoma theragnostic agent","volume":"53","author":"Camacho","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2016.05.025_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000338961","article-title":"[99mTc(CO)3]-radiolabeled Bevacizumab: in vitro and in vivo evaluation in a melanoma model","volume":"84","author":"Camacho","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.apradiso.2016.05.025_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.apradiso.2016.05.025_bib7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.nucmedbio.2013.05.011","article-title":"Tracer level radiochemistry to clinical dose preparation of 177Lu labelled cyclic RGD peptide dimer","volume":"40","author":"Chakraborty","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.apradiso.2016.05.025_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10967-014-3169-z","article-title":"On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience","volume":"302","author":"Chakraborty","year":"2014","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.apradiso.2016.05.025_bib9","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1167\/iovs.10-6862","article-title":"PET\/CT Imaging of I-124 radiolabeled Bevacizumab and Ranibizumab after intravitreal injection in a rabbit model","volume":"52","author":"Christoforidis","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.apradiso.2016.05.025_bib10","first-page":"172","article-title":"Expression of vascular permeability factor\/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis and experimental metastasis","volume":"56","author":"Claffey","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.apradiso.2016.05.025_bib11","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1021\/jm060317v","article-title":"Small animal PET\/CT imaging using 86Y-CHX-A\u2032\u2032-octreotide: validation of a novel CHX-A\u2032\u2032 derivative suitable for peptide conjugation","volume":"49","author":"Clifford","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.apradiso.2016.05.025_bib12","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.ejca.2008.07.042","article-title":"The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?","volume":"44","author":"Eskens","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.apradiso.2016.05.025_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1524\/ract.2007.95.6.351","article-title":"177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: a comparative study using DOTA and DTPA chelating systems","volume":"95","author":"Fani","year":"2007","journal-title":"Radiochim. Acta"},{"key":"10.1016\/j.apradiso.2016.05.025_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ics.2003.11.003","article-title":"VEGF and its receptors","volume":"1262","author":"Ferrara","year":"2004","journal-title":"Int. Congr. Ser."},{"key":"10.1016\/j.apradiso.2016.05.025_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.9-suppl_1-2","article-title":"Vascular endothelial growth factor as a target for anticancer therapy","volume":"9","author":"Ferrara","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.apradiso.2016.05.025_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.apradiso.2016.05.025_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.apradiso.2016.05.025_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000088479","article-title":"VEGF as a therapeutic target in cancer","volume":"69","author":"Ferrara","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.apradiso.2016.05.025_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.apradiso.2016.05.025_bib20","series-title":"Table of Isotopes","author":"Firestone","year":"1996"},{"key":"10.1016\/j.apradiso.2016.05.025_bib21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.0022-202X.2004.23460.x","article-title":"Overproduction of VEGF165 concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling","volume":"123","author":"Graells","year":"2004","journal-title":"J. Invest. Dermatol."},{"issue":"Suppl. 1","key":"10.1016\/j.apradiso.2016.05.025_bib22","first-page":"S1","article-title":"Angiogenesis as a new target for cancer control","author":"Harris","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.apradiso.2016.05.025_bib23","first-page":"503","article-title":"DTPA-coupled antibodies labeled with yttrium-90","volume":"26","author":"Hnatowich","year":"1985","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2016.05.025_bib24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s12149-014-0887-9","article-title":"Preparation of 99mTc carbonyl DTPA-Bevacizumab and its bioevaluation in a melanoma model","volume":"28","author":"Kameswaran","year":"2014","journal-title":"Ann. Nucl. Med"},{"key":"10.1016\/j.apradiso.2016.05.025_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1089\/cbr.2015.1836","article-title":"Evaluation of the potential of 177Lu-CHX-A\u2032\u2032-DTPA-Rituximab as a radioimmunotherapeutic agent for Non-Hodgkin's Lymphoma","volume":"30","author":"Kameswaran","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.apradiso.2016.05.025_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.apradiso.2016.05.025_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20856","article-title":"Therapeutic efficacy of 177Lu-CHX-A\u2033-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy","volume":"69","author":"Kelly","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.apradiso.2016.05.025_bib28","first-page":"878","article-title":"Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 21T-BAT-Lym-1 immunoconjugates","volume":"55","author":"Kukis","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.apradiso.2016.05.025_bib29","doi-asserted-by":"crossref","first-page":"7080s","DOI":"10.1158\/1078-0432.CCR-1004-0019","article-title":"Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A\u2032\u2032-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478","volume":"11","author":"Lee","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.apradiso.2016.05.025_bib30","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.addr.2008.04.006","article-title":"Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides","volume":"60","author":"Liu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.apradiso.2016.05.025_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.apradiso.2016.05.025_bib32","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood.V98.6.1904","article-title":"Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor\u2013positive human tumors","volume":"98","author":"Masood","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.apradiso.2016.05.025_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-200868040-00009","article-title":"Bevacizumab: a review of its use in metastatic colorectal cancer","volume":"68","author":"McCormack","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.apradiso.2016.05.025_bib34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/annonc\/mdi208","article-title":"Bevacizumab - current status and future directions","volume":"16","author":"Midgley","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.apradiso.2016.05.025_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/nrd1601","article-title":"Bevacizumab","volume":"3","author":"Muhsin","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.apradiso.2016.05.025_bib36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2967\/jnumed.107.041301","article-title":"In vivo VEGF imaging with radiolabeled Bevacizumab in a human ovarian tumor xenograft","volume":"48","author":"Nagengast","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2016.05.025_bib37","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2010","journal-title":"Curr. Drug. Targets"},{"key":"10.1016\/j.apradiso.2016.05.025_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1349-7006.2010.01763.x","article-title":"Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts","volume":"102","author":"Paudyal","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.apradiso.2016.05.025_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/bc00016a014","article-title":"Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates","volume":"3","author":"Pippin","year":"1992","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.apradiso.2016.05.025_bib40","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.apradiso.2016.05.025_bib41","first-page":"534","article-title":"The role of VEGF in melanoma progression","volume":"17","author":"Rajabi","year":"2012","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.apradiso.2016.05.025_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph5010001","article-title":"Pre-clinical assessment of 177Lu-labeled Trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease","volume":"5","author":"Ray","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apradiso.2016.05.025_bib43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1006\/cyto.1999.0566","article-title":"Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine down regulates VEGF production in vitro","volume":"12","author":"Redondo","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.apradiso.2016.05.025_bib44","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.apradiso.2016.05.025_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/mabs.2.2.11360","article-title":"The\u00a0VEGF\u00a0family\u00a0in\u00a0cancer\u00a0and\u00a0antibody-based\u00a0strategies\u00a0for their\u00a0inhibition","volume":"2","author":"Sullivan","year":"2010","journal-title":"mAbs"},{"key":"10.1016\/j.apradiso.2016.05.025_bib46","first-page":"544","article-title":"An approach for conjugation of 177Lu-DOTA-SCN-Rituximab (BioSim) and its evaluation for radioimmunotherapy of relapsed and refractory B-cell Non Hodgkins lymphoma patients","volume":"139","author":"Thakral","year":"2014","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.apradiso.2016.05.025_bib47","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10967-014-3240-9","article-title":"Aspects of yield and specific activity of (n,\u03b3) produced 177Lu used in targeted radionuclide therapy","volume":"302","author":"Vimalnath","year":"2014","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.apradiso.2016.05.025_bib48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14728222.2011.641951","article-title":"Targeting the VEGF signaling pathway in cancer therapy","volume":"16","author":"Waldner","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.apradiso.2016.05.025_bib49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0969-8051(03)00019-2","article-title":"Targeting of renal carcinoma with 67\/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging","volume":"30","author":"Zimmermann","year":"2003","journal-title":"Nucl. Med. Biol."}],"container-title":["Applied Radiation and Isotopes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804316302007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804316302007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T10:26:55Z","timestamp":1656584815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969804316302007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":49,"alternative-id":["S0969804316302007"],"URL":"https:\/\/doi.org\/10.1016\/j.apradiso.2016.05.025","relation":{},"ISSN":["0969-8043"],"issn-type":[{"value":"0969-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of 177Lu-CHX-A\u2032\u2032-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers","name":"articletitle","label":"Article Title"},{"value":"Applied Radiation and Isotopes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apradiso.2016.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}